Case Report

Therapy Side Effects in Systemic Lupus Erythematosus

ROMEO POPA¹, LOREDANA-ADRIANA LAUTARU², RADU LUCRETIU³, DANIELA CANA RUINI⁴, DANIEL CARAGEA⁴, MAGDALENA OLTEANU⁴, ALEXANDRU RADU MIHAILOVICI⁵, CRISTINA ENE¹, VLAD PADUREANU⁶, RODICA PADUREANU⁷, VALENTIN CIRILIG⁸

¹PhD student, Department of University of Medicine and Pharmacy of Craiova, Romania
²Student of Dental Medicine of University of Medicine and Pharmacy of Craiova, Romania
³Department of Hygiene, Faculty of Nursing and Midwives, University of Medicine and Pharmacy of Craiova, Romania
⁴Department of Nephrology, Faculty of Nursing and Midwives, University of Medicine and Pharmacy of Craiova, Romania
⁵Department of Cardiology, Emergency Country Hospital of Craiova, Romania
⁶Department of Internal Medicine, University of Medicine and Pharmacy of Craiova, Romania
⁷PhD Student Biochemistry Department, University of Medicine and Pharmacy of Craiova, Romania
⁸Department of Pharmacology, University of Medicine and Pharmacy of Craiova, Romania

ABSTRACT: Glucosteroids (GS) are widely used drugs for various inflammatory pathologies (Nephrotic syndrome, Proliferative glomerulonephritis, Extramembrane glomerulonephritis, Nephropathy of the Nodous Poliardertita (PAN), Nephropathy from purple Henoch-Schonlein, lupus nephropathy (LN), Acute adrenal insufficiency Waterhouse-Friederichsen, Chronic adrenal insufficiency Addison, Systemic Lupus Erythematosus (SLE), Polymyositis and dermatomyositis, Chronic granulomatosis, Crohn's disease, Hemorrhagic rectocolitis, Hemolytic anemias, Acute leukemias and chronic lymphocytic leukemia, Hodgkin's lymphoma). Although they are prescribed for their anti-inflammatory and immunosuppressive properties, they also have many side effects, hyperglycemia being one of the most common and representative, which is why these drugs need careful monitoring when administered over the long term. This paper presents the case of a 39 year old patient diagnosed with systemic lupus erythematosus (SLE) with class IV lupus nephropathy (LN) who developed numerous complications due to the pathogenic side effects: diabetes, amenorrhea, recurrent infections, and depression.

KEYWORDS: Corticotherapy, systemic erythematosus lupus, cortico-induced diabetes

Introduction

SLE is an autoimmune disease in the collagenosis group with systemic pathogenesis which, besides the immune imbalance, involves a whole series of genetic, environmental and hormonal factors.

Autoimmune diseases are defined as conditions in which the immune response to certain autoantigens is the cause of tissue damage.

SLE affects predominantly female sex (80-90%), suggesting an involvement of estrogenic hormones in the pathogenesis of the disease.

The evolution of the disease is marked by periods of exacerbation and remission [1,2] but also by a whole series of complications: carbohydrate metabolism, protein, lipid metabolism, hydro-electrolyte disorders and disorders of endocrine, ophthalmic, dermatological, neuropsychiatric [1,3], LN occurs in 40-75% of the patients and is one of the most serious lesions of organ from SLE [4]. GS are widely used drugs in acute or chronic inflammatory pathology seen in Table 1

| Renal affections | Cortico adrenal affections | Collagenosis | Pulmonary affections | Digestive affections | Hematological affections |
|------------------|--------------------------|--------------|----------------------|---------------------|-------------------------|
| Nephrotic syndrome | Acute adrenal insufficiency | SLE | Chronic Bronchitis intense | Crohn's disease | Acute leukemias and chronic lymphocytic leukemia |
|                   | Waterhouse-Friederichsen |              |                      |                     |                         |

Table 1. Indication of glucosteroids in various pathologies
Proliferative glomerulonephritis | Chronic adrenal insufficiency Addison | PAN | Bronchial asthma | Hemorrhagic rectocolitis | Thrombocytopenic purpura
---|---|---|---|---|---
Extramembrane glomerulonephritis | Polymyositis and dermatomyositis | | | | Hodgkin's lymphoma
Nephropathy from purple Henoch-Schonlein | Chronic granulomatosis | | | | Hemolytic anemias
Nephropathy of the Nodous Polyarteritis (PAN) | | | | | Hemolytic anemias
LN

GS reduce the synthesis of proinflammatory cytokines, Fc receptor antibody expression, T cell function, which activate anti-inflammatory and immunosuppressive processes, thus laying the foundations of SLE treatment [1].

Despite their effectiveness, their use is limited by the variety of associated side effects, and close monitoring is required (Table 2) [5].

**Table 2. Side effects of the glucocorticoids [5]**

| SIDE EFFECT of Prednisone | TIME DEPENDENT | DOSE DEPENDENT | THE MINIMUM DOSE RESPONSIBLE FOR THE OCCURRENCE OF THE EFFECTS, ADVERSE (mg) |
|---|---|---|---|
| Osteoporosis | Yes | Yes | 5 |
| Hyperglycemia | Yes | Yes | 2.5 |
| Cushing's Syndrome | Yes | Yes | 5 |
| Cardiovascular disease | Yes | Yes | 7.5 |
| Increasing the risk of infection | Yes | Yes | 5-7.5 |
| Dermatology | Yes | Yes | Undefined |
| Glaucoma | Yes | Yes | 7.5 |
| Cataract | Yes | Yes | 6 |
| Psychological and behavioral | Yes | Yes | Undefined |

Corticoid-induced diabetes, one of the most common adverse effects of glucocorticoids, is defined as an abnormal increase in serum glucose associated with their use in a patient with or without a history of Diabetes Mellitus (DM) [6].

Some of the risk factors for DM corticoinduced could be the dose and duration of action of the drug, but also traditional factors such as: patient age, heredo-collateral history, glucose tolerance, body mass index (BMI) [7].

From the pathophysiological point of view GS administration leads to increased gluconeogenesis and glycogen synthesis, eventually leading to the development of DM [8].

The diagnostic criteria of DM developed by the American Diabetes Association take into account:

- the glycemic value of jeun≥7.0mmol/L (126mg/dl), 2 hours after the oral glucose tolerance test (OGTT) ≥11.1mmol/200mg/dl),
- glycosylated hemoglobin (HbA1c)≥6.5% or patients with value of serum glycemia at any time of the day >11,1mmol/l (200mg/dl) [5].

HbA1c is useful in diagnosing DM in patients treated with corticosteroids for a period of 2 to 3 months, but not for patients whose treatment has been recently initiated.

Recently, Japanese researchers have developed an algorithm for cortico induced DM diagnosis suggesting that HbA1c level monitoring is of real importance. Patients who may be false elevated with HbA1c are those with hemoglobinopathy, renal insufficiency or anemia/recent blood transfusions or those with Hb1Ac within normal limits when initiating corticosteroid therapy, therefore measuring serum fructosamine value would be a better alternative [7].

Fructosamine is a marker of glycemic control over the past 2-3 weeks. Fructosamine has not gained popularity as Hb1Ac for DM control, the reasons being still unclear [9].

Therefore, the most useful criterion for the diagnosis of corticosteroid diabetes in most patients is serum glucose level >200mg/dl at any time of the day [1].
Case Report

The present paper presents the case of a 30-year-old rural smoker who presented herself in January 2016 at the Carol Davila Bucharest Nephrology Hospital with elevated TA (190/100mmHg), lower limb edema, arthralgia of the elbow and knee.

The clinical examination revealed the general altered condition of the patient, high blood pressure (TA=190/100mmHg), palpebral and sural edema and polyarthralgia, the rest of the clinical picture being within normal limits.

Laboratory data revealed the modified immunological profile, with elevated immune circulating complexes (CIC) values, low complement C3, high perinuclear Anti-Neutrophil Cytoplasmic Antibodies (pANCA), increased anti-ADN antibody, nephrotic proteinuria 3.6g/24h, dysmorphic red blood cells in the urine summary.

### Table 3. Biological immunological balance

| No | Investigation         | Result            |
|----|-----------------------|-------------------|
| 1  | CIC                   | 79,5 R.U/ml       |
| 2  | IgG                   | 1284mg/dl         |
| 3  | IgA                   | 234,2mg/dl        |
| 4  | IgM                   | 149mg/dl          |
| 5  | complement 3          | 38,49g/L          |
| 6  | cANCA                 | <0,2u/ml          |
| 7  | pANCA                 | 35u/ml            |
| 8  | lupic anticoagulant   | Positive          |
| 9  | antcardiolipin antibody| >80GPL/ml        |

Corroborating the outcome of clinical and paraclinical data, suspicion of SLE with renal impairment was raised. In order to confirm the diagnosis, renal biopsy puncture was done, which established the diagnosis of glomerulonephritis lupus class IV with extra capillary proliferation, required initiation of corticosteroid therapy (methylprednisolone 1g for 3 days, then prednisone 1mg/kg for 30 days with gradual dose reduction, 10mg/day every 2 weeks up to a dose of 40mg/kg, cyclophosphamide 600mg intravenous/2 weeks, 3 pulses).

After about 2 weeks, renal function improvement and proteinuria reduction were obtained.

After about 7 months of remission, the patient discontinues immunosuppressive therapy on her own initiative, returning after 12 months with a creatinine value of 11.86g/dl, proteinuria/24h=6.9g/dl, serum albumin=2.2g/dl, for which reasons it was decided to admit to the Nephrology Clinic of the County Emergency Clinical Hospital from Craiova for further investigations and adequate therapeutic behavior.

### Table 4. Evolving inflammatory syndrome

| No | Result           | Result after GS initiation |
|----|------------------|---------------------------|
| 1  | VSH              | 27mm/1h                   |
| 2  | Fibrinogen       | 329mg/dl                  |
| 3  | PCR              | 4,6mg/l                   |
| 4  | Ferritin         | ng/ml                     |

### Table 5. Biological balance in evolution

| No | Investigation | Admission result | Result after initiation of GS and HD |
|----|---------------|------------------|--------------------------------------|
| 1  | Hb            | 10,1g/dl         | 8,2g/dl                              |
| 2  | Leukocytes    | 6450mm3          | 12410mm3                             |
| 3  | Platelets     | 23500mm3         | 111240mm3                            |
| 4  | Urea          | 173mg/dl         | 207mg/dl                             |
| 5  | Creatinine    | 11,8mg/dl        | 12,5                                 |
| 6  | eRFG           | 4ml/min/1,73m2   | <4ml/min/1,73m2                       |
| 7  | alkaline reserve | 17mEq/l    | 20mEq/l                              |
| 8  | uric acide    | 6,33mg/dl        |                                       |
| 9  | Cholesterol   | 220mg/dl         |                                       |
| 10 | Triglycerides | 121mg/dl         |                                       |
| 11 | Glycemia      | 97mg/dl          | 150mg/dl 6 o clock                   |
| 12 | HB1Ac         | 4,8%             | 169-97mg/dl 18 o clock               |
| 13 | Calcium       | 7,1mg/dl         | 8,3mg/dl                             |
| 14 | Phosphorus    | 10,9 mg/dl       |                                       |
| 15 | IPTH          | 227,8pg/l        |                                       |
| 16 | Total proteins| 4,6 g/dl         | 5g/dl                                |
| 17 | Seric albumin | 2,6g/dl          | 2,8g/dl                              |
| 18 | Urinal summary exam | Proteinuria-2.5g/24h; 8.7g/24h, numerous red blood cell | MRSa |
| 32 | sputa BK, bacteriological | MRSA | MRSA |
| 33 | Seric ionogram | Na132mEq/l | 124mEq/l |
|    |                 | K 5,4mEq/l       | 6,5-3,6mEq/l                          |
Clinical examination has shown a general condition of an influenced patient, pale mucus, dehydrated, irregular skin lesions, exfoliated at the face and upper limbs level, massive sural edema and palpebral, stethacoustic pulmonary, no over added rales, TA=180/100mmHg, AV=40b/min (sinus bradycardia), rhythmic cardiac noises, pulsating peripheral arteries.

Urine summary: confirmed nephrotic serum, proteinuria/24h=8.94g, important inflammatory syndrome was shown in Table 3 and 4.

Electrocardiogram (EKG): does not reveal any special changes.

Abdominal-pelvic ultrasound: hepatosplenomegaly with homogeneous ecosostructure, medium ascites fluid, VC1=21mm, both long-sleeved kidneys about 12.5cm, IP=1.5cm with hyperchogenic parenchyma, well differentiated pyramids, deleting differentiation cortico-medullary, without dilation of the urinary tract.

The following diagnoses have been made: systemic lupus erythematosus with lupus apophysis class IV with extracapillary proliferation, Corticoinduced diabetes mellitus, pANCA vasculitis, Antiphospholipid syndrome, Aggravated chronic kidney disease, treated by hemodialysis, secondary nephrotic syndrome, Hypoproteinemia with hypoalbuminemia, Moderate hypercholesterolemia, Secondary hypertension, Moderate secondary anemia, Mild hyperuricemia Secondary hyperparathyroidism, Moderate hypocalcaemia, Severe hyperphosphatemia, Metabolic acidosis.

In the therapy of the patient, targets were aimed at reducing systemic inflammation, decreasing disease activity, achieving remission of the disease, resuming diuresis and renal function, preventing relapse, counteracting the risk of complications, comorbidities and side effects associated with corticotherapy.

Non-pharmacological treatment was chosen to avoid cold, dampness, intense physical effort and exposure to the sun, and contraindications such as: smoking, alcohol consumption, water intake greater than 500ml. The diet should be hyperproteic, hypocarbohydrate, hypo-sodium, hypolipidic, with low purine intake.

The pharmacological treatment of SLE and vascular pANCA was related to the systemic and renal activity which required the initiation of pulse-therapy with methylprednisolone 1g iv for 3 days, then Prednisone 1mg/kg 30 with a decrease of 10mg/day from the dose to 2 weeks, until the dose is 40mg/day, then the dose will decrease by 5mg/day until you have a dose of 10mg/day and cyclophosphamide 600mg IV at 2 weeks 3 pulses.

For antiphospholipid syndrome, we have received antiagregant, anticoagulant treatment as the anti-cardiolipin antibody titer was increased, the activated thromboplastin time is low, thus presenting a high risk of thromboembolic events.

The treatment of cardiovascular complications included loop diuretics, calcium receptor blockers, and statins. Low heart rate did not allow the administration of beta blockers.

For the complications of phosphocalcic metabolism were admitted: lactic calcium, phosphorus chelators.

Repeated clinical and paraclinical balance after initiation of corticotherapy was revealed in Table 5.

Considering the important nitrate retention (creatinine=12mg/dl, urea=207mg/dl), acid-base and hydro-electrolyte imbalance, oligoanuria and clinical evolution of the patient, it was decided to initiate renal replacement therapy by hemodialysis on CVC, is obtaining partial correction of hypoalbuminemia: 2.6—2.9mg/dl. The increase in glycemia (67mg/dl→140mg/dl) secondary to immunosuppressive therapy led to the diagnosis of secondary corticosteroid DM and hypoglucid diet with 250g carbohydrates in 5 meals was recommended. The Psychological and Psychiatric Examination established the diagnosis of corticosteroid-induced anxiety adjustment disorder.

The patient presented secondary under fever to a respiratory interference (productive cough, pulmonary stethacoustic, bronchial rallies) radiologically-increased vascular drawing, enlarged hills in the projection area. Bacteriological sputum revealed methicillin resistant Staphylococcus aureus (MRSA) thus allowing the formulation of the diagnosis of acute MRSA pneumopathy, subsequently treated with Clarithromycin 500mg 2 tablets/day 7 days (according to the antibiogram).

**Discussion**

GS played an important role in the pathogenic therapy of SLE, but their management also brought a whole series of adverse effects, especially those that were administrated in the long term, but can occurred in the short term. These were endocrine side effects (amenorrhea, azoospermia, Corticosuprenalne hypoplasia), metabolic (DM, hyperglycemia), bone, dermatological (purpura, acne, hirsutism), ophthalmology (cataract,
reversible glaucoma, myopia) psychological and psychiatric (psychoses, depressions nervousness, euphoria) [3,10,11]. These were mainly linked to the mechanism of genomic action and were dose-dependent and therapy duration-dependent [1].

At the metabolic level, glucocorticoids increased the risk of hyperglycemia in both DM and non-DM patients [1], as was the case with this patient displaying elevated blood glucose levels approximately 3 days after initiation of corticotherapy.

The patient was being monitored glycemic at the time of admission, but also during GS therapy, because nearly 94% of cases of hyperglycemia developed within 1-2 days of initiating steroid therapy in non-diabetic patients. If you maintained your blood sugar <140mg/dl without having insulin about 24-48 hours, glycemic monitoring may be interrupted [5], according to specialized publications.

The GS effect is usually transient and reversible. As steroid doses were reduced, their effect on endocrine metabolism returned to initial value, and GS-induced diabetes will be remitted; however, this was not a general rule [1,4].

Another apparent side effect after GS in this case was Pneumonia with MRSA, because these drugs had an immunosuppressive effect, resulting in a decrease in the number of elements responsible for the immune process, so there is a decrease in anti-infectious protection [3], being a cause the importance of morbidity and mortality in many inflammatory pathologies. This adverse effect were dose-dependent and treatment duration-dependent, although the literature was not accurate if there was a limit threshold below which glucocorticoid therapy was safe [5]. However, lung infections also occurred in clinical manifestations of SLE is dry or wet pleurisies (40 to 60%); lupus pneumonia and pulmonary fibrosis are rare [2]. no additional investigations were required in view of the favorable progression of the patient from the pulmonary point of view.

Another apparent adverse effect of GS administration was amenorrhea being affirmed anamnesis, not being investigated endocrinologically and gynecologically during admission.

According to GS, at high doses it lowers estrogen and testosterone levels, but infertility or decreased libido has not been established, but may also be a secondary premature ovarian failure SLE [9].

Glucocorticoids could have caused psychological and behavioral disorders, including mood disorders, sleep and psychosis, as has been seen in the patient's case. The most common side effects of glucocorticoid treatment are short-term euphoria and hypomania, while long-term therapy could induce depressive symptoms. These disorders were dose related and may occurred immediately after initiation of treatment, sometimes requiring association of GS with neurosedatives [12], but considering the patient's mild symptomatology, no medical treatment was required.

The prognosis and progression of the patient after approximately 6 months was favorable in terms of systemic SLE activity and secondary side effects of GS therapy, but it was not favorable for lupus nephritis because nitrate retention and anuria was counter-sparing for discontinuation of renal substitution therapy through hemodialysis. This case accounts for 25-30% of patients who do not respond to treatment is associated with worse renal outcomes [13].

**Conclusion**

The widespread use of GS in the medical field requires careful monitoring of patients in order to diagnose and correct the adverse effects of these therapeutic agents. Early detection of adverse events associated with corticotherapy is required by careful monitoring of biological constants to prevent the development of diabetes, infections, glaucoma, cataracts, cardiovascular disease, osteoporosis, major depression.

Immunosuppressive medication is a challenge for the clinician by dosing and continuously adjusting doses according to the clinical-biological status of the patient with the objective of reducing the activity of the disease and minimizing adverse effects.

**Abbreviations**

Glucosteroids (GS), systemic lupus erythematosus (SLE), lupus nephropathy (LN), Nodous Poliarterita (PAN), Diabetes mellitus (DM), Body mass index (BMI), glycosylated hemoglobin (HbA 1c), blood pressure (TA), immune circulating complexes (CIC), anti-neutrophil cytoplasmic antibodies (p-ANCA), Cytoplasmatic antineutrophil cytoplasmic antibodies (c-ANCA) renal biopsy puncture (PBR), methicillin resistant Staphylococcus aureus (MRSA).
Acknowledgments
The first and the second author contributed equally to the manuscript.

References
1. Héctor ET, Dania LQ, René RG, José GG, Alejandra LT. Steroid hyperglycemia: Prevalence, early detection and therapeutic recommendations: A narrative review. World J Diabetes, 2015, 6(8):1073-1081.
2. Blank M, Shoenfeld Y, Perl A. Cross-talk of the environment with the host genome and the immune system thorough endogenous retroviruses in systemic lupus erythematosus. Lupus, 2009, 18(13):1136-1143.
3. Schächke H, Döcke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther, 2002, 96(1):23-43.
4. P Alba, Bento L, Cuadrado MJ, Y Karim, Tunegkar MF, Abbs I, Khamashta MA, D'Cruz D, Hughes GRV. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis, 2003, 62(6):556-560.
5. Guillermo R-I, Alvaro DMK. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford), 2012, 51(7):1145-1153.
6. Silvio I, Richard B, Vivian F, Edward G, Beth MD, Geralyn S, Richard W. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 2010, 33(1):S62-S69.
7. Kim SY, Yoo CG, Lee CT. Incidence and Risk Factors of Steroid-induced Diabetes in Patients with Respiratory Disease. J Core Med Sci, 2011, 26(2):264-267.
8. Satyanarayanasetty D, Pawar K, Nadig P, Haran. A Multiple Adverse Effects of Systemic Corticosteroids: A Case Report. J Clin Diagn Res, 2015, 9(5):e007689.
9. Jobert RN, Joël FD, Jean JN, Eric V, Eugène S, André P K. Fructosamine measurement for diabetes mellitus diagnosis and monitoring: a systematic review and meta-analysis. BMJ Open, 2015, 5(5):1-5.
10. Fujii N, Hamano T, Mikami S, Nagasawa Y, Isaka Y, Moriyama T, Horio M, Imai E, Hori M, Ito T. Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active active vitamin D (PRIUS-CKD). Nephrol Dial Transplant. 2007, 22(6):1601-1607.
11. L David, DL Veenstra, HJ Best, SD Sullivan, DE Hricik. The incidence and long-term cost of side-effects related to steroids after renal transplantation. The American Journal of Renal Disease, 1999, 33(5):829-39.
12. Warrington TP, Bostwick JM. Psychiatric Adverse Effects of Corticosteroids. Mayo Clin Proc, 2006, 81(10):1361-1367.
13. Aziz F, Chaudhary K. Lupus Nephritis: A Treatment Update. Curr Clin Pharmacol, 2018, 13(1):4-13.

Corresponding Author: Alexandru Radu Mihailovici, Department of Cardiology, Emergency Country Hospital of Craiova, 2 Petru Rares Street, 200349 Craiova, Romania, E-mail: drmihailovici@yahoo.com